Cancers · 2022 · 40 citations · 44 references
MedicineCancer BiologyOncologyCancer ImmunologyGynecologic OncologyTumor MicroenvironmentCancer ImmunotherapyImmuno-oncology BiomarkersPersonalized Cancer TherapyPreclinical Cancer ModelsTargeted Cancer TherapyTargeted Therapy3D Tumor ModelsImmuno-oncology ModelsOvarian Cancer BiomarkersOvarian Cancer Tumor MicroenvironmentReverse-phase Protein MicroarraysTherapeutic Response PredictionTumor Microenvironment BiomarkersTumor Microenvironment Modeling
In light of the frequent development of therapeutic resistance in cancer treatment, there is a strong need for personalized model systems representing patient tumor heterogeneity, while enabling parallel drug testing and identification of appropriate treatment responses in individual patients. Using ovarian cancer as a prime example of a heterogeneous tumor disease, we developed a 3D preclinical tumor model comprised of patient-derived microtumors (PDM) and autologous tumor-infiltrating lymphocytes (TILs) to identify individual treatment vulnerabilities and validate chemo-, immuno- and targeted therapy efficacies. Enzymatic digestion of primary ovarian cancer tissue and cultivation in defined serum-free media allowed rapid and efficient recovery of PDM, while preserving histopathological features of corresponding patient tumor tissue. Reverse-phase protein array (RPPA)-analyses of >110 total and phospho-proteins enabled the identification of patient-specific sensitivities to standard, platinum-based therapy and thereby the prediction of potential treatment-responders. Co-cultures of PDM and autologous TILs for individual efficacy testing of immune checkpoint inhibitor treatment demonstrated patient-specific enhancement of cytotoxic TIL activity by this therapeutic approach. Combining protein pathway analysis and drug efficacy testing of PDM enables drug mode-of-action analyses and therapeutic sensitivity prediction within a clinically relevant time frame after surgery. Follow-up studies in larger cohorts are currently under way to further evaluate the applicability of this platform to support clinical decision making.
44
Integrated genomic analyses of ovarian carcinoma
Debra Bell, Andrew Berchuck, Narciso Olvera et al. · Nature · 2011 · 8.2K citations · Full text
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Lin Zhang, José R. Conejo-García, Dionyssios Katsaros et al. · New England Journal of Medicine · 2003 · 3.4K citations · Full text
Medicine, Immunology, Oncology +17
Eiichi Sato, Sara H. Olson, Jiyoung Ahn et al. · Proceedings of the National Academy of Sciences · 2005 · 2.4K citations · Full text
Life Sciences, Immunology, Oncology +17